Skip to main content

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

Trial Status: Closed to Accrual

The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.

Inclusion Criteria

  • Diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction
  • Completed pre-operative chemo radiotherapy followed by surgery
  • Diagnosed with residual pathologic disease after being surgically rendered free of disease with negative margins following complete resection

Exclusion Criteria

  • Diagnosed with cervical esophageal carcinoma
  • Diagnosed with Stage IV resectable disease
  • Did not receive concurrent chemoradiotherapy prior to surgery
  • Participants who have received a live/attenuated vaccine within 30 days of the first treatment

California

Los Angeles
USC / Norris Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
San Francisco
UCSF Medical Center-Mount Zion
Status: CLOSED_TO_ACCRUAL
Contact: Jennifer Luan
Phone: 415-514-6220

Colorado

Aurora
University of Colorado Hospital
Status: CLOSED_TO_ACCRUAL
Contact: Sarah Lindsey Davis
Phone: 303-724-8681

District of Columbia

Washington
MedStar Georgetown University Hospital
Status: ACTIVE

Florida

Miami
University of Miami Miller School of Medicine-Sylvester Cancer Center
Status: CLOSED_TO_ACCRUAL

Illinois

Chicago
University of Chicago Comprehensive Cancer Center
Status: ACTIVE
Contact: Daniel Virgil Thomas Catenacci
Phone: 773-834-0475

Maryland

Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: ACTIVE
Contact: Ronan Joseph Kelly
Phone: 410-502-3696

Massachusetts

Boston
Beth Israel Deaconess Medical Center
Status: CLOSED_TO_ACCRUAL
Contact: James Mark Cleary
Phone: 617-632-9265
Brigham and Women's Hospital
Status: CLOSED_TO_ACCRUAL
Contact: James Mark Cleary
Phone: 877-442-3324
Dana-Farber Cancer Institute
Status: CLOSED_TO_ACCRUAL
Contact: James Mark Cleary
Phone: 617-632-5588
Massachusetts General Hospital Cancer Center
Status: CLOSED_TO_ACCRUAL
Danvers
Mass General / North Shore Cancer Center
Status: COMPLETED

Missouri

Saint Louis
Siteman Cancer Center at Washington University
Status: CLOSED_TO_ACCRUAL
Contact: Haeseong Park
Phone: 314-747-7401

New Jersey

Hackensack
Hackensack University Medical Center
Status: ACTIVE

New York

Bronx
Montefiore Medical Center-Weiler Hospital
Status: CLOSED_TO_ACCRUAL
New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Status: CLOSED_TO_ACCRUAL

North Carolina

Durham
Duke University Medical Center
Status: ACTIVE
Contact: Hope Elizabeth Uronis
Phone: 919-668-1861

Ohio

Cleveland
Case Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Jennifer Eads

Oregon

Portland
OHSU Knight Cancer Institute
Status: CLOSED_TO_ACCRUAL

Pennsylvania

Philadelphia
Fox Chase Cancer Center
Status: CLOSED_TO_ACCRUAL

Tennessee

Nashville
Vanderbilt University / Ingram Cancer Center
Status: CLOSED_TO_ACCRUAL

Texas

Houston
M D Anderson Cancer Center
Status: CLOSED_TO_ACCRUAL

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: CLOSED_TO_ACCRUAL
Contact: Veena Shankaran
Phone: 206-667-7844

Wisconsin

Madison
University of Wisconsin Hospital and Clinics
Status: CLOSED_TO_ACCRUAL

Trial Phase Phase III

Trial Type Treatment

Lead Organization
Bristol-Myers Squibb

  • Primary ID CA209-577
  • Secondary IDs NCI-2016-00858, 2015-005556-10, s16-00474
  • Clinicaltrials.gov ID NCT02743494